Alzumab (Psoriasis)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 13
3.2 Symptoms 16
4 Disease Management 17
4.1 Treatment Overview 18
5 Competitive Assessment 22
5.1 Overview 22
5.2 Strategic Competitor Assessment 23
6 Opportunity and Unmet Need 24
6.1 Overview 24
6.2 Unmet Needs 25
6.2.1 Improved Drug Safety and Efficacy Profiles 25
6.2.2 Biomarkers for Predicting Remission 26
6.2.3 More Cost-Effective Therapies Through Oral Formulation and Biosimilars 26
6.2.4 Education and Treatment of Psychological Factors Accompanying Psoriasis 27
6.2.5 An Effective Biologic/Systemic Topical Therapy 27
6.2.6 More Effective Treatment for Mild Psoriasis, Specifically UV Therapies 28
6.2.7 Physician Education About the Different Types of Psoriasis, not Just Plaque Psoriasis 28
6.3 Opportunities 29
6.4 Unmet Needs Gap Analysis 29
6.4.1 Predictive Tools for Diagnosis and Treatment 30
6.4.2 Target Specificity 30
6.4.3 Topical Biologic/Systemic Therapeutic Options 31
6.4.4 Helping Patients with Psychological Issues Associated with Psoriasis 31
7 Pipeline Assessment 32
7.1 Overview 32
7.2 Promising Drugs in Clinical Development 33
8 Alzumab (itolizumab) 35
8.1 Overview 35
8.2 Efficacy 36
8.3 Safety 37
8.4 Dosing and Formulation 37
8.5 Potential Clinical Positioning 37
8.6 Potential Commercial Positioning 37
8.7 Pricing and Reimbursement 37
8.8 SWOT Analysis 38
8.9 Forecast 39
9 Appendix 40
9.1 Bibliography 40
9.2 Abbreviations 42
9.3 Methodology 45
9.4 Forecasting Methodology 45
9.4.1 Diagnosed Psoriasis Patients 45
9.4.2 Percent Drug-Treated Patients 46
9.4.3 General Pricing Assumptions 46
9.4.4 Generic Erosion 47
9.4.5 Pricing of Pipeline agents 47
9.5 Physicians and Specialists Included in this Study 48
9.6 Primary Research – Prescriber Survey 49
9.7 About the Authors 50
9.7.1 Analysts 50
9.7.2 Global Head of Healthcare 51
9.8 About GlobalData 52
9.9 Disclaimer 52